Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice

Abstract The progestin-based hormonal contraceptive Depot Medroxyprogesterone Acetate (DMPA) is widely used in sub-Saharan Africa, where HIV-1 is endemic. Meta-analyses have shown that women using DMPA are 40% more likely than women not using hormonal contraceptives to acquire Human Immunodeficiency...

Full description

Bibliographic Details
Main Authors: Jocelyn M. Wessels, Philip V. Nguyen, Danielle Vitali, Kristen Mueller, Fatemeh Vahedi, Allison M. Felker, Haley A. Dupont, Puja Bagri, Chris P. Verschoor, Alexandre Deshiere, Tony Mazzulli, Michel J. Tremblay, Ali A. Ashkar, Charu Kaushic
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-83242-9
id doaj-2c3623001ed1450a83368b237c5f59e6
record_format Article
spelling doaj-2c3623001ed1450a83368b237c5f59e62021-02-21T12:33:23ZengNature Publishing GroupScientific Reports2045-23222021-02-0111111610.1038/s41598-021-83242-9Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized miceJocelyn M. Wessels0Philip V. Nguyen1Danielle Vitali2Kristen Mueller3Fatemeh Vahedi4Allison M. Felker5Haley A. Dupont6Puja Bagri7Chris P. Verschoor8Alexandre Deshiere9Tony Mazzulli10Michel J. Tremblay11Ali A. Ashkar12Charu Kaushic13McMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityDepartment of Pathology and Molecular Medicine, McMaster UniversityAxe Des Maladies Infectieuses Et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Pavillon CHULPublic Health Laboratories, Public Health OntarioAxe Des Maladies Infectieuses Et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Pavillon CHULMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityMcMaster Immunology Research Centre, Michael G. DeGroote Centre for Learning and Discovery, McMaster UniversityAbstract The progestin-based hormonal contraceptive Depot Medroxyprogesterone Acetate (DMPA) is widely used in sub-Saharan Africa, where HIV-1 is endemic. Meta-analyses have shown that women using DMPA are 40% more likely than women not using hormonal contraceptives to acquire Human Immunodeficiency Virus (HIV-1). Therefore understanding how DMPA increases susceptibility to HIV-1 is an important public health issue. Using C57BL/6 mice and our previously optimized humanized mouse model (NOD-Rag1 tm1Mom Il2rg tm1Wjl transplanted with hCD34-enriched hematopoietic stem cells; Hu-mice) where peripheral blood and tissues are reconstituted by human immune cells, we assessed how DMPA affected mucosal barrier function, HIV-1 susceptibility, viral titres, and target cells compared to mice in the diestrus phase of the estrous cycle, when endogenous progesterone is highest. We found that DMPA enhanced FITC-dextran dye leakage from the vaginal tract into the systemic circulation, enhanced target cells (hCD68+ macrophages, hCD4+ T cells) in the vaginal tract and peripheral blood (hCD45+hCD3+hCD4+hCCR5+ T cells), increased the rate of intravaginal HIV-1 infection, extended the window of vulnerability, and lowered vaginal viral titres following infection. These findings suggest DMPA may enhance susceptibility to HIV-1 in Hu-mice by impairing the vaginal epithelial barrier, increasing vaginal target cells (including macrophages), and extending the period of time during which Hu-mice are susceptible to infection; mechanisms that might also affect HIV-1 susceptibility in women.https://doi.org/10.1038/s41598-021-83242-9
collection DOAJ
language English
format Article
sources DOAJ
author Jocelyn M. Wessels
Philip V. Nguyen
Danielle Vitali
Kristen Mueller
Fatemeh Vahedi
Allison M. Felker
Haley A. Dupont
Puja Bagri
Chris P. Verschoor
Alexandre Deshiere
Tony Mazzulli
Michel J. Tremblay
Ali A. Ashkar
Charu Kaushic
spellingShingle Jocelyn M. Wessels
Philip V. Nguyen
Danielle Vitali
Kristen Mueller
Fatemeh Vahedi
Allison M. Felker
Haley A. Dupont
Puja Bagri
Chris P. Verschoor
Alexandre Deshiere
Tony Mazzulli
Michel J. Tremblay
Ali A. Ashkar
Charu Kaushic
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
Scientific Reports
author_facet Jocelyn M. Wessels
Philip V. Nguyen
Danielle Vitali
Kristen Mueller
Fatemeh Vahedi
Allison M. Felker
Haley A. Dupont
Puja Bagri
Chris P. Verschoor
Alexandre Deshiere
Tony Mazzulli
Michel J. Tremblay
Ali A. Ashkar
Charu Kaushic
author_sort Jocelyn M. Wessels
title Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
title_short Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
title_full Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
title_fullStr Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
title_full_unstemmed Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
title_sort depot medroxyprogesterone acetate (dmpa) enhances susceptibility and increases the window of vulnerability to hiv-1 in humanized mice
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2021-02-01
description Abstract The progestin-based hormonal contraceptive Depot Medroxyprogesterone Acetate (DMPA) is widely used in sub-Saharan Africa, where HIV-1 is endemic. Meta-analyses have shown that women using DMPA are 40% more likely than women not using hormonal contraceptives to acquire Human Immunodeficiency Virus (HIV-1). Therefore understanding how DMPA increases susceptibility to HIV-1 is an important public health issue. Using C57BL/6 mice and our previously optimized humanized mouse model (NOD-Rag1 tm1Mom Il2rg tm1Wjl transplanted with hCD34-enriched hematopoietic stem cells; Hu-mice) where peripheral blood and tissues are reconstituted by human immune cells, we assessed how DMPA affected mucosal barrier function, HIV-1 susceptibility, viral titres, and target cells compared to mice in the diestrus phase of the estrous cycle, when endogenous progesterone is highest. We found that DMPA enhanced FITC-dextran dye leakage from the vaginal tract into the systemic circulation, enhanced target cells (hCD68+ macrophages, hCD4+ T cells) in the vaginal tract and peripheral blood (hCD45+hCD3+hCD4+hCCR5+ T cells), increased the rate of intravaginal HIV-1 infection, extended the window of vulnerability, and lowered vaginal viral titres following infection. These findings suggest DMPA may enhance susceptibility to HIV-1 in Hu-mice by impairing the vaginal epithelial barrier, increasing vaginal target cells (including macrophages), and extending the period of time during which Hu-mice are susceptible to infection; mechanisms that might also affect HIV-1 susceptibility in women.
url https://doi.org/10.1038/s41598-021-83242-9
work_keys_str_mv AT jocelynmwessels depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT philipvnguyen depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT daniellevitali depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT kristenmueller depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT fatemehvahedi depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT allisonmfelker depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT haleyadupont depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT pujabagri depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT chrispverschoor depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT alexandredeshiere depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT tonymazzulli depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT micheljtremblay depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT aliaashkar depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
AT charukaushic depotmedroxyprogesteroneacetatedmpaenhancessusceptibilityandincreasesthewindowofvulnerabilitytohiv1inhumanizedmice
_version_ 1724257898063724544